Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “BIOMARIN PHARMACEUTICAL INC.”

112 pharma patents match "BIOMARIN PHARMACEUTICAL INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 112
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 112 pharmaceutical patents matching "BIOMARIN PHARMACEUTICAL INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

112 results for “BIOMARIN PHARMACEUTICAL INC.” · 30,257 patents in full index Clear search

  1. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  2. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  3. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  4. US 12188058

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  5. US 12076372

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  6. US 11918633

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  7. US 11911446

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  8. US 11821008

    Liver targeting adeno-associated viral vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  9. US 11739345

    Methods of treating phenylketonuria

    BIOMARIN PHARMACEUTICAL INC. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  10. US 11690898

    Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  11. US 11590204

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  12. US 11584780

    Adeno-associated virus capsid proteins

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  13. US 11505790

    Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  14. US 11406690

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  15. US 11384055

    Glycolate oxidase inhibitors for the treatment of disease

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  16. US 11358932

    N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  17. US 11351231

    Lysosomal targeting peptides and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  18. US 11345904

    Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  19. US 11254725

    Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  20. US 11229687

    TPP-1 formulations and methods for treating CLN2 disease

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  21. US 11202819

    Use of C-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  22. US 11040088

    Delivery of therapeutic compounds to the brain and other tissues

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  23. US 10934534

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  24. US 10851058

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted